



Community & Stakeholder Engagement in HIV Cure-Related Research




CUREiculum

This research training curriculum is a collaborative project aimed at making the science of HIV cure-related research accessible to the community and the HIV research field.

Outline

- “Nothing About Us Without Us”
- How Can We Define Stakeholders??
- How Can We Define Community?
- Where Does Engagement Fit?
- What Principles Make Good Engagement?
- Why Is Engagement Important?
- Engagement in HIV Cure-Related Research
- Why is Stakeholder Engagement Important?
- The Paramount Importance of Community-Friendly Information
- Examples and Ideas

“Nothing About Us Without Us”



The Denver Principles, 1983





The Denver Principles (1983)

Statement from the People with AIDS advisory committee

We condemn attempts to label us as "victims," a term which implies defeat, and we are only occasionally "patients," a term which implies passivity, helplessness, and dependence upon the care of others.

We are "People With AIDS."

RECOMMENDATIONS FOR ALL PEOPLE

1. Support us in our struggle against those who would fire us from our jobs, evict us from our homes, refuse to touch us or separate us from our loved ones, our community or our peers, since available evidence does not support the view that AIDS can be spread by casual, social contact.
2. Not scapegoat people with AIDS, blame us for the epidemic or generalize about our lifestyles.



RECOMMENDATIONS FOR PEOPLE WITH AIDS

1. Form caucuses to choose their own representatives, to deal with the media, to choose their own agenda and to plan their own strategies.
2. Be involved at every level of decision-making and specifically serve on the boards of directors of provider organizations.
3. Be included in all AIDS forums with equal credibility as other participants, to share their own experiences and knowledge.
4. Substitute low-risk sexual behaviors for those which could endanger themselves or their partners; we feel people with AIDS have an ethical responsibility to inform their potential sexual partners of their health status.

RIGHTS OF PEOPLE WITH AIDS

1. To as full and satisfying sexual and emotional lives as anyone else.
2. To quality medical treatment and quality social service provision without discrimination of any form including sexual orientation, gender, diagnosis, economic status or race.
3. To full explanations of all medical procedures and risks, to choose or refuse their treatment modalities, to refuse to participate in research without jeopardizing their treatment and to make informed decisions about their lives.
4. To privacy, to confidentiality of medical records, to human respect and to choose who their significant others are.
5. To die – and to LIVE – in dignity.

Denver 1983

The Greater Involvement of People Living with HIV (GIPA)

Policy Brief The Greater Involvement of People Living with HIV (GIPA)

Context

Nearly 40 million people in the world are living with HIV.¹ In countries such as Botswana and Swaziland, people living with HIV make up a quarter or more of the population.

People living with HIV are entitled to the same human rights as everyone else, including the right to access appropriate services, gender equality,² self-determination and participation in decisions affecting their quality of life, and freedom from discrimination.³

All national governments and leading development institutions have committed to meeting the eight Millennium Development Goals, which include halving extreme poverty, halting and beginning to reverse HIV⁴ and providing universal primary education by 2015. GIPA or the Greater Involvement of People Living with HIV is critical to halting and reversing the epidemic in many countries reversing the epidemic is also critical to reducing poverty.

What is GIPA?

GIPA is not a project or programme. It is a principle that aims to realize the rights and responsibilities of people living with HIV, including their right to self-determination and participation in decision-making processes that affect their lives. In these efforts, GIPA also aims to enhance the quality and effectiveness of the AIDS response.

The idea that personal experiences should shape the AIDS response was first voiced by people living with HIV at the 1994 Paris AIDS Summit when 42 countries agreed to "support a greater involvement of people living with HIV at all...levels...and to...stimulate the creation of supportive political, legal and social environments".⁵

In 2001, 189 United Nations member countries endorsed the GIPA Principle as part of the Declaration of Commitment on HIV/AIDS. The 2006 Political Declaration on HIV/AIDS unanimously adopted by 192 Member States

Why GIPA?

People living with HIV have directly experienced the greater involvement of people living with HIV.

People living with HIV have directly experienced factors that make individuals and communities vulnerable to HIV infection—and once infected, the HIV-related illnesses and strategies for managing them. Their involvement in programme development and implementation in policy-making will improve the relevance and effectiveness of programmes. Meaningful involvement of people living with HIV in policy-making and effectiveness of programmes. Meaningful involvement of people living with HIV in policy-making and effectiveness of programmes. Meaningful involvement of people living with HIV in policy-making and effectiveness of programmes.

The engagement of people living with HIV in decision-making processes is more urgent as countries scale up responses to achieve the goal of universal access to prevention, treatment, care and support.

The benefits of GIPA are many: increased morale, decreased isolation, improved health through access to prevention. With the involvement of people living with HIV, as well as providing value to the community and people living with HIV by showing their voices being heard and demonstrating their contributions to the response.

Openly acknowledged demobilises

The participation and contribution of people living with HIV is one of the best examples of global progress in public health.

We have come from a place where people openly living with HIV were stoned to death, to a place where we have been invited to stand among the leaders of the world to shape international policies.

There is still a long way to walk but we have made historical changes and gains of which we can be proud.

- Gracia Violeta Ross

National Chair, Bolivian Network of People Living with HIV/AIDS



The Meaningful Involvement of People Living with HIV (MIPA)

- intentional engagement of people living with HIV in leadership, advisory, and decision-making roles
- critical to ensure that the voices of people most affected by an issue or decision are heard



How Can People Living with HIV Be Involved?




Figure 1:
How can people living with HIV be involved?




How Can We Define Stakeholders?




How Can We Define Stakeholders?

- Global Stakeholders
- National Stakeholders
- Broader stakeholders
- Community Stakeholders
- Trial Participants/Potential Participants




community engagement

...WHO ARE YOU 'ENGAGING?'



How Can We Define Community?



How Can We Define Community?


“A group of people with diverse characteristics who are linked by social ties, share common perspectives, and engage in joint action in geographical locations or settings.”

(MacQueen, 2001)

“who is included and who is excluded from membership”
(Institute of Medicine, 1995)



Where Does Engagement Fit?



Good Clinical Practice is **NOT** Good Participatory Practice



Research
Investigator



Good Clinical Practice



Trial Participants



Research teams
(and trial sponsors
and funders)



Good Participatory Practice



Stakeholders



Why Do We Engage Beyond the Participant?

PrEP research trial controversy

- 2004 – Cambodia trials were not initiated
- 2005 – Cameroon and Nigeria trials discontinued




The background of the slide features a repeating pattern of interlocking puzzle pieces. The top and bottom sections are light gray with a faint gray puzzle piece outline pattern. The central section is a solid magenta color, also featuring a faint gray puzzle piece outline pattern. Scattered across the magenta section are several white puzzle pieces, some of which are solid and others are just outlines.

What Principles Make Good Engagement?

Guiding Principles of Engagement



How Do We Engage?



Understanding how community engagement with research works

Leads to

Research
Engagement
activities



Meet, Talk, Discuss

Interactions

Show respect, wide
consultation, listen,
understand each
other



When this goes well

Exchange of understandings in regular meaningful interactions
increases sense of **being heard and respected** and **builds trust**

Wide consultation builds **acceptance of research as having social value**
and a sense that it responds to community needs and concerns

Responsiveness of research process increases **motivation
to engage**

Meaningful involvement increases **community 'buy-in'**, willingness to
participate in the research, and sense that it is partly theirs

Address
community
concerns

Community
support for and
participation
in research


Better, more
relevant
research


Research
contributes
to better
health in
future




Engagement Throughout Entire Study Cycle

Day S et al. *Journal of the International AIDS Society* 2018, **21**(S7):e25174
<http://onlinelibrary.wiley.com/doi/10.1002/jia2.25174/full> | <https://doi.org/10.1002/jia2.25174>






Why is Engagement Important?



Landscape of Engagement



Research in the Age of Fast Media

- Headlines aren't always accurate
- Potential to spread rumors
- Potential to erode trust



***“Cure for HIV
possible within
three years as
scientists snip
virus from cells”
-Telegraph, 2016***



The background of the slide features a repeating pattern of interlocking puzzle pieces. The top and bottom sections are light gray with a faint gray puzzle piece pattern. The central section is a solid magenta color. Scattered throughout the magenta section are several white puzzle pieces of various shapes and orientations. The text is centered in the magenta section in a large, bold, white font.

Engagement in HIV Cure-Related Research

Engagement in HIV Cure-Related Research

- **Education and transparency** are key goals that stakeholder advisory mechanisms must strive to incorporate
- Critical that all stakeholders, **including health care providers**, understand how early phase cure related research can benefit future populations
- **Developing comprehensive engagement plans** that reflect sociocultural norms and stakeholder needs are crucial to advancing research aims



Formative Research Activities

Allows the research team to understand:

- Informed understanding of local populations
- Socio-cultural norms
- Local power dynamics
- Local perceptions
- Channels of communication
- Site selection



Stakeholder Engagement Plan

- **Communication component**
 - Policies and strategies to increase broad awareness of the trial and facilitate accurate dissemination of research
- **Education component**
 - Key to building research literacy and empowering community stakeholders as decision-making agents



Policies on Trial-Related Harm

How research teams will treat and compensate trial participants

- **Physical harms:** include any negative physical event
- **Social harms:** non-medical consequences such as
 - Social isolation
 - Stigma or discrimination
 - Employment or housing loss
 - Difficulties in personal relationships



The background of the slide features a repeating pattern of interlocking puzzle pieces. The top and bottom sections are light gray with a faint gray puzzle piece pattern. The central section is a solid purple band. Scattered within this purple band are several white puzzle pieces, some of which are solid and others are just outlines. The main title is centered in this purple band in a large, white, sans-serif font.

Why is Stakeholder Engagement Important?

**Four Common
(Mis)CONCEPTIONS
in HIV Cure-Related
Research**

I. Community engagement **is not recruitment for clinical research.**

2. Community engagement and community advisory boards serve related but different purposes.

3. Community engagement and education is not merely community service.

4. Community engagement.
is not research or ethics.

ENGAGEMENT IS...

the creation of **relationships**

individuals & groups

*local, national
& international*

ALIGN INTERESTS



CO-CREATION

FOLLOWING THESE PRINCIPLES:

RESPECT

MUTUAL UNDERSTANDING

INTEGRITY



CUREiculum



www.avac.org/gpp



TRANSPARENCY

ACCOUNTABILITY

AUTONOMY

community engagement

Community & Patient Engagement

Creation of relationships

Management of expectations

Sharing of information

Meaningful dialogue

Mutual literacy and understanding

Community Advisory Boards

Input into research process

Sounding board

Protocol or research review

Critical safeguard in research process

Recruitment for Clinical Research

Populations of interest

Eligibility screening

Enrollment in clinical research

Meaningful dialogue

Research

Systematic work

Generalizable knowledge


Research methods


Informed consent

Trust, Mutual Respect, Transparency, Autonomy



The Need for Consensus on Best Practices for Community and Stakeholder Engagement in Early-Phase (HIV Cure) Research



A close-up photograph of a hand placing a single red puzzle piece into a larger assembly of white puzzle pieces. The hand is positioned on the left side of the frame, with the index finger and thumb carefully guiding the red piece into place. The white puzzle pieces are already partially assembled, forming a textured surface. The background is dark and out of focus, emphasizing the hand and the puzzle pieces.

*What should
community &
stakeholder
engagement look like
in the **context of**
early-phase, basic
and translational
HIV cure research?*

- May need **deliberative process to define best practices**






- Need **practical, applied model** for engagement



- **Make people living with HIV and community feel comfortable giving input**



- May also mean **building capacity of researchers** to value community input



- Need to **plan for the long-term** (*may not be specific to a trial*)



The Paramount Importance of Community-Friendly Information

The Paramount Importance of **Community-Friendly** Information

- Need to **invest in community scientific literacy** and in scientific literacy around community concerns

The Paramount Importance of **Community-Friendly** Information

- Pay attention to **language choice**

The Paramount Importance of **Community-Friendly** Information

- **Engage former study participants**, as this can be a powerful way to share information about studies and build trust

Lessons from $U = U$

The Research: HPTN 052

The Implementation: Treatment as Prevention

The Translation: $U = U$

The Policy: End the Epidemic (U.S.), 95 95 95



Credit: Dazon Dixon Diallo, SisterLove, Inc.

Minority Participation in Clinical Research

Dialogues on
Diversifying
Clinical Trials



Successful Strategies for Engaging Women and
Minorities in Clinical Trials

Whites account
for 66.9% of the
total U.S. population,
but make up
83.3% of trial
participants.³²

Between 1985 and
2008, the percentage
of AIDS cases
increased in
African-
Americans by
30%.²⁶

“How do we know that
research that’s
primarily done on
young, White, healthy
males can be
extrapolated
to women?”

Phyllis Greenberger,
President and CEO of the
Society for Women’s Health
Research

65-80% of
African-
Americans
and
Hispanics
would be willing to
provide
essential biological
samples such
as blood and DNA.²⁸

Minority patients more often seek care from physicians of
their own race.³⁷



Finding a Clinical Research Study

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies ▾

About Studies ▾

Submit Studies ▾

Resources ▾

About Site ▾

[PRS Login](#)

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

Explore 365,419 research studies in all 50 states and in 219 countries.

See [listed clinical studies](#) related to the coronavirus disease (COVID-19)

ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

Find a study (all fields optional)

Status ⓘ

- ☐ Recruiting and not yet recruiting studies
- ☒ All studies

Condition or disease ⓘ (For example: breast cancer)



CUREiculum

Finding a Clinical Research Study



TAG’s **Research Towards a Cure**
webpage: <https://www.treatmentactiongroup.org/cure/trials/>

Trial	Trial Registry Identifier(s)	Sponsor(s)	Phase	Estimated End Date/Interim Results
ADOPTIVE IMMUNOTHERAPY				
AutoRESIST: HIV antigen-specific T-cells targeting conserved epitopes for treatment of HIV-associated lymphoma	NCT04975698	Catherine Bollard, Children’s Research Institute	Phase II	June 2026
AlloRESIST: Evaluate the safety, immunologic, and virologic responses of donor derived HIV-specific T-cells in HIV+ individuals	NCT04248192	Catherine Bollard, Children’s Research Institute	Phase I	April 2024


Finding a Clinical Research Study

The ACTG conducts offers a wide range of studies for people with HIV: <https://actgnetwork.org/studies/>




Questions?





ACKNOWLEDGMENTS



Module developers:

Morénike Gina Onaiwu, ACTG

William B Carter, BEAT-HIV CAB

Beth Peterson, BEAT-HIV CAB


Jeff Taylor, CARE & DARE CABs

Danielle Campbell, DARE CAB

Michael Louella, defeatHIV CAB

Christopher Roebuck, BEAT-HIV CAB

Karine Dubé, UNC Chapel Hill



We wish to thank **AIDS Treatment Activists Coalition**
for the funding to complete this module

*Their caring support of the CUREiculum 2.0.
will make a difference in the lives of thousands.
of people living with HIV*

We would like to thank
Jessica Salzwedel
(AVAC) for contributions
to developing the initial
CUREiculum module on
community and
stakeholder engagement.



The image features a central purple rectangular area. Above and below this area are horizontal bands with a repeating pattern of interlocking puzzle pieces in a light gray color. Scattered within the purple area are six individual puzzle pieces: three are solid white and three are white outlines. They are positioned at various angles, some pointing towards the center and others away from it.

Examples and Ideas



Publications

BEAT-HIV CAB POSITION PAPER


The product of a partnership among the BEAT-HIV Community Advisory Board (CAB), BEAT-HIV principal investigators, clinical researchers, and pioneering community health center Philadelphia FIGHT, this paper is written with the community in mind.

It's meant to clarify and demystify HIV cure-directed studies, especially those that employ an analytical treatment interruption (ATI).

DOWNLOAD THE PAPER: <https://beat-hiv.org/ati-position-paper/>



CUREiculum



community engagement

BEAT-HIV CAB POSITION PAPER

They took a “**trauma-informed approach**” in developing this paper, because many people living with HIV are impacted by lifetime individual- and community-level trauma.



MODULE 3:
Considerations for Navigating the Informed Consent Process in an HIV Cure-directed Study

MODULE 1:
What is an Analytical Treatment Interruption (ATI)?
Why are they used in HIV cure-directed research?

SUMMARY POINTS

- ART interruption remains the best measure to evaluate HIV cure-directed investigational strategies, particularly those that work by an activation of the immune system towards control or eradication of HIV once ART is stopped.
- Closely monitored ART interruption as a component of a cure-directed study is justified if prior research has shown that the drug or curative strategy being studied has demonstrated, in laboratory settings, a potential efficacy justifying its testing in people living with HIV.
- The primary risks of a long-term interruption of ART are the onset of HIV viral rebound (i.e., HIV becomes detectable) and reduction in CD4 count (a type of immune cell).
- Additional risks of therapy interruption also include a) the potential for development of resistance against anti-HIV medicines, b) HIV disease progression, and c) the risk of HIV transmission to other people.
- Make sure you understand the study sequence (i.e., what will happen when), the informed consent documents, and discuss what personal issues you may need to consider.
- Discussing study participation with your significant other or partners, if warranted, should also be recommended as ATIs may present a transmission risk.
- Above all, ask questions, get informed, and only proceed when you (not just your provider) fully understand the risks and that participation is right for you.

formation
s in language
ly questions

consent process is
an important aspect
study.

n with

n to who
they

ning of
right,
in study

a),
ms

23

11

BEAT-HIV Position Paper / beat-hiv.org

WHY SEARCH FOR A CURE?

BEAT-HIV: Game Changers Trailer

The paper contains five **educational modules** with linked videos featuring community members and researchers.

To advance **research literacy**,
you must engage potential
study participants and their
communities, **HIV researchers**,
healthcare providers, **funding**
agencies, and others looking to
support **HIV cure research**.



THE BEAT-HIV POSITION PAPER'S TOP TEN POINTS

1. Participation in a clinical study takes time and commitment. It is very important for potential participants to understand the time required for study visits and procedures and the length of the study. Joining a clinical trial may affect a participant's life schedule and may impact their relationship(s) or family, so it is important that when considering whether to join an HIV-cure directed study, potential participants discuss their decision with family and friends and their health care providers.
2. Both sex and gender matter in HIV cure-directed research. Study participant distribution must be sex and gender balanced, and data to be collected must address relevant emotional and social factors.
3. There are multiple barriers women face when participating in research, including competing life demands, i.e. scheduling, childcare, transportation, and access to information about HIV cure-directed clinical trials. Researchers should take these barriers into consideration as they design studies to facilitate the inclusion of women and meet women where they are in their lives.
4. Inclusion of cis- and trans-gender women is imperative for HIV-cure research so that when a cure is found, it will be both accessible and affirming for all people.
5. The informed consent process is one of the most important aspects of any clinical study. The informed consent process provides information about a research study, explains participants' rights and responsibilities in plain language, provides the space to raise any and all questions that potential participants may have about the study. The informed consent form should also clearly state that you participate only because you want to and that you are free to leave the study at any time.
6. Potential clinical study participants should understand that if they consent to enroll in a cure-directed study, the hope and the expectation is that they will be able to complete the study. However, this does not mean that they give up their right to stop participating in the study at any time without any consequences. Their ongoing participation in any clinical study is completely voluntary.
7. When reviewing the informed consent form, potential participants should pay special attention to who is sponsoring the study, what potential side effects could be expected and how those side effects will be addressed.
8. Analytic treatment interruption (ATI) is a closely monitored pause of antiretroviral therapy as part of a research study. The purpose of the pause in treatment is to determine the effect of the intervention on viral load compared to standard antiretroviral therapy.
9. ATIs remain the best way to evaluate HIV cure-directed strategies, particularly those that work with the immune system.
10. Any interruption of therapy may result in viral rebound, which must be carefully monitored. Viral rebound also carries risks of HIV transmission. Be sure to know how to protect your partner(s) and what laws cover the sexual transmission of HIV in the localities where you have sex. Remember study staff are there to help you answer any questions you have.

The image features a central magenta band with the text "Amplify community voices" in white. This band is flanked by two horizontal borders of a repeating puzzle piece pattern. Scattered across the magenta band are eight individual puzzle pieces: four are solid white and four are white outlines. They are positioned at various angles and locations, including top-left, top-center, top-right, bottom-left, bottom-center, and bottom-right.



Amplify community voices




AMPLIFY THE VOICES IN YOUR COMMUNITY

Create activities that allow people to express their thoughts about an HIV cure.

- collect anonymously
- or feature the person as well as what they say
- can be shared in many ways

- newsletters
- emails
- websites
- social media
- posters
- abstracts
- magazines








They asked Global Village attendees from around the world.
to write on paper leaves their answers to the question,
“What would an HIV cure mean to you?”



Respondents included clinicians, researchers, policy-makers, people with HIV, activists, and others.





What Would an HIV Cure Mean to You?

Ascribing Meaning Through an HIV Cure Tree

Laurie Sylla¹, Michael Louella¹, David Evans^{2,3}, Jeff Taylor⁴, Richard Jefferys⁵, Karine Dubé⁶

¹ defeatHIV Community Advisory Board (CAB), Seattle, Washington; ² Project Inform, Los Angeles, California; ³ Delaney AIDS Research Enterprise (DARE) CAB, Los Angeles, California; ⁴ Collaboratory of AIDS Researchers for Eradication (CARE) CAB, Palm Springs, CA; ⁵ Treatment Action Group, New York, NY; ⁶ UNC Chapel Hill, Chapel Hill, NC

Background

Interest and investment in HIV cure research has been increasing since the apparent cure of Timothy Ray Brown 10 years ago through a bone marrow transplant from a donor homozygous for the CCR5-delta 32 mutation. While his experience has not yet been replicated and is still not fully understood, it spawned the burgeoning field of HIV cure research. An HIV cure holds the possibility of being transformative societally as well as medically. Little has been explored about the meaning and value individuals ascribe to a cure.

Methods

Volunteers from the national Community Advisory Board (CAB) of the Martin Delaney Collaboratory (MDC), a US National Institutes of Health initiative funding multiple HIV cure research collaboratories created an "HIV Cure Tree" at the 2016 IAS Conference Global Village in Durban, South Africa. MDC CAB volunteers asked a convenience sample of Global Village attendees from around the world to write on paper leaves their answers to the question, "What would an HIV Cure Mean to You?" Respondents included clinicians, researchers, people living with HIV, activists, and others. Upon return to the US, a demographically diverse group of members of the Seattle-based defeatHIV Community Advisory Board, an MDC local site, broke into small groups and engaged in a pile sort activity to group the leaves into themes. This was supplemented by creation of a word cloud using the words from the leaves.

CHARACTERIZATION OF LEAF THEMES (n = 244), 2016											
GROUP 1	GROUP 2	GROUP 3	GROUP 4	GROUP 5	GROUP 6	GROUP 7	GROUP 8	GROUP 9	GROUP 10	GROUP 11	GROUP 12
Freedom	34	Hope	48	Freedom	47	Life/Peace	64	Freedom	71	Social	93
Hope	16	Freedom	44	Hope	26	No more!	42	Life	71	Individual	93
Economics/Cost	14	Health	39	Life	23	Freedom	14	Future	65	Abstract Science	34
Happiness/Wellbeing	14	Love	18	Cure	19	Treatment	26	???	33	Science	17
Stigma	14	Education	16	Removal of stigma	19	Misery	22			Science process	7
Relief	13	Relief	16	Optimism	17	Family	14			Abstract science	1
Victory	12	Peace	13	Prosperity	13	Intentionality	14				
Misc	12	Misc	10	Future	11	Feeling	9				
HIV/AIDS free	11	Research	9	???	10	Language					
Children	10	Educational	6	Happiness	9						
Future	10	Money	6	Societal benefit	9						
Unity	9	Fears	3	Determination	7						
End of death	8	Family/Religion		Religion	6						
End of Suffering	8	Peace		Peace	6						
No more needs	7	Peace		Peace	6						
Peace	7	Policy		Peace	6						
Prevention	6	Prevention		Peace	6						
Time	6	Time		Peace	6						
Faith/Values	5	Love		Peace	6						
Love	4	New beginnings		Peace	6						
New beginnings	3	Love		Peace	6						
Research	2	Love		Peace	6						
Love	2	Love		Peace	6						

Results

We collected 244 leaves. The most dominant themes were freedom, hope and life. Themes related to peace, relief, stigma, happiness and the future were also significant. Examples of leaves related to freedom included freedom from the virus, freedom from stigma, freedom from medication, and freedom from worry.

Acknowledgements

We would like to thank all the people who visited our booth in The Global Village at AIDS 2016. We also thank Moses Supercharger for giving us the seed of this idea to engage people around HIV cure research and David Palm for his help in our planning process. As well, we thank members of the Martin Delaney Collaboratory Community Advisory Board (CAB), including the members of the CABs for the Collaboratory of AIDS Researchers for Eradication (CARE), Delaney AIDS Research Enterprise (DARE) and defeatHIV.

Conclusions

People see an HIV cure as liberating for both individuals and societies. Many perceive it as the best route to ending stigma and a key element contributing to ending AIDS. Personal and social meanings connected to cure were of paramount importance to individuals. Cultural context contributes to the meanings people ascribe to a cure. There is significant global support for continuing to search for an HIV cure.

Afterwards, members of the Seattle-based defeatHIV Community Advisory Board sorted the paper leaves into themes.

A **word cloud** was created from the 244 responses, morphing the words into the shape of a tree.

MDC CAB members then **wrote an abstract** based on the themes **and submitted it** to the 2017 IAS conference.

9TH IAS CONFERENCE ON HIV SCIENCE
PARIS, FRANCE – 23-26 JULY 2017

The abstract was accepted for poster presentation at the conference, and the word cloud was used as a central image.


After the conference, MDC CAB members submitted the word cloud for publication in the 2017 Sept-Oct issue of *Positively Aware*

**The resulting article, “Tree of Life”,
appeared in print and online on Sep 6,
2017.**

<https://www.positivelyaware.com/articles/tree-life>

**The resulting article, “Tree of Life”,
appeared in print and online on Sep 6,
2017.**

<https://www.positivelyaware.com/articles/tree-life>



ILLUSTRATION

...A word cloud was created from the 244 responses, and the words morphed into a tree. The word tree was presented in a presentation at IAS 2017. "That it captures the most common themes while preserving all the voices that answered our question was a great source of interest at IAS, especially for those living with HIV," said Michael Louella.

POSITIVELY AWARE SEPTEMBER + OCTOBER 2017 41

The background of the slide features a repeating pattern of interlocking puzzle pieces in a light gray color. A solid purple horizontal band runs across the middle of the slide, containing the text and several white puzzle piece icons. The top and bottom edges of the slide also show the puzzle piece pattern.

Poster presentations

Barriers to HIV Cure Research Participation Among Persons Living With and Without HIV

THE GEORGE
WASHINGTON
UNIVERSITY

WASHINGTON, DC

Cheriko A. Boone, MSW, MPH^{1,3}; Amanda D. Castel, MD, MPH²; A. Toni Young^{3,4}; Eleanor Sarkodie, MPH^{3,5}; Richard Strange³; Thomas J. Villa³; Nancy Caballero-Suarez, PhD^{3,6}; Evelyn Rodriguez-Estrada, MD^{3,6}; Jon Fenech³; Daniel Barros, MPH^{3,7}; Terry Howard, MScPPH³; Andre Ceranto³; Jane Kanyinda, MPH²; Many Magnus, PhD, MPH²

¹The George Washington University, Department of Psychology; ²The George Washington University, Milken Institute School of Public Health;

³Community Advisory Board (as of June 2019), BELIEVE Collaboratory for HIV Cure Research at Weill-Cornell Medicine; ⁴Executive Director, Community Education Group

⁵Whitman-Walker Health; ⁶Centro de Investigación en Enfermedades Infecciosas (CIENI) - Instituto Nacional de Enfermedades Respiratorias (INER); ⁷University of Sao Paulo

Milken Institute School
of Public Health

THE GEORGE WASHINGTON UNIVERSITY

BACKGROUND

Functional and sterilizing HIV cures are on the horizon, with early trials of curative approaches underway. The majority of research on attitudes about HIV cure has focused on persons living with HIV (PLWH) and has not included HIV-negative persons, thereby limiting our understanding of other communities who may influence the willingness of PLWH to enroll in current and future safety or efficacy clinical trials. In order to inform clinical trial recruitment strategies, we sought to characterize knowledge, attitudes, and perceptions of HIV cure research among PLWH and HIV-negative individuals.

METHODS

- Data were collected from an anonymous online convenience sample of adults (N = 185) between 9/2017 and 7/2018.
- Correlates of barriers to study participation were examined using logistic regression.
- Factor analysis was used to construct a 7-item scale of HIV cure pessimism; and linear regression was used to assess predictors of HIV cure pessimism, stratified by HIV status.

RESULTS

While the perception of what an HIV cure meant and willingness to participate in invasive and/or high risk cure trials differed by HIV status, there were no differences ($p < 0.05$) in what motivated willingness to participate (WTP).

Table 1: Characteristics of Survey Participants (N=185)	%
Age (median) [IQR]	(37) [28-49]
Self-identified male	55.9
Self-identified female	41.8
Self-identified transgender (female-to-male)	0.5
Self-identified other gender	2.7
Lives in East Coast, United States	41.8
Lives in Southern United States	9.9
Lives in Midwest, United States	6.6
Outside the United States	7.7
Living with HIV [44% > 20 years]	27.0
Family or friends living with HIV	32.4
Self-perceived risk for contracting HIV	14.0
Black/African American	24.3
College degree or higher	79.7

Table 2: Perceptions of HIV Cure Research and Eventual Cure Uptake | HIV Pessimism Scale (N = 185)

Survey Item	Strongly Agree/Agree		Strongly Disagree/Disagree	
Scale: 1 = Strongly Agree 2 = Agree 3 = Neutral/Not sure 4 = Disagree 5 = Strongly Disagree	HIV negative (n = 135)	HIV positive (n = 50)	HIV negative (n = 135)	HIV positive (n = 50)
	N (%)	N (%)	N (%)	N (%)
Cost will prevent people from taking it*	101 (82.1)	39 (81.3)	14 (11.4)	1 (2.1)
The dangers of a new cure may be too high*	27 (22.0)	19 (39.6)	36 (29.3)	7 (14.6)
Current ARV is very good; we do not need a cure	7 (5.7)	4 (8.3)	102 (83.6)	38 (79.2)
If a cure were available for HIV, people will not use PrEP and other methods to stay HIV negative	32 (26.0)	15 (31.3)	66 (53.7)	19 (39.6)
More education is needed before HIV cure will be accepted by the community*	80 (65.0)	30 (63.8)	13 (10.6)	12 (25.5)
I do not think there will ever be a cure	10 (8.1)	5 (10.4)	89 (72.4)	29 (60.4)
A cure that would stop the need for all HIV treatment is desirable (reverse-coded)	114 (93.4)	44 (91.7)	3 (2.5)	1 (2.1)
I can trust my healthcare provider's decision on which medical treatments are best for me**	70 (57.4)	40 (83.3)	22 (18.0)	2 (4.2)
All things considered, I completely trust my healthcare provider***	54 (43.9)	38 (79.2)	30 (24.4)	4 (8.3)

Chi-square comparing strongly agree/agree vs not sure vs strongly disagree/disagree:


* $p < 0.05$ ** $p < 0.01$ *** $p < 0.001$

Bold items included in HIV Cure Pessimism Scale (Cronbach's $\alpha = 0.59$, standardized)

For each %, denominator excludes missing responses and "neutral/not sure" responses

Negative perceptions of HIV cure differed significantly based on HIV status: HIV-negative respondents more likely to perceive cost ($p < 0.05$) and lack of trust in healthcare providers ($p < 0.01$) as barriers; and PLWH were more likely to perceive risks of treatment ($p < 0.05$) and lack of community education as barriers ($p < 0.05$) (see Table 2).

After adjusting for confounders, HIV-negative persons identifying as Black/Asian/multiracial/Latinx had higher HIV cure pessimism scores than persons who identified as White ($p < 0.05$). Among PLWH, women had higher HIV cure pessimism scores than men ($p < 0.05$).



CONCLUSIONS

- Understanding barriers to HIV cure research participation is critical as we develop novel curative therapies.
- Knowledge of barriers and facilitators of HIV cure research participation is essential to preemptively prepare for social and behavioral implications of eventual dissemination.
- Salient differences between PLWH and HIV-negative persons deserve consideration when developing strategies for recruitment and community engagement in cure research.

FUTURE DIRECTIONS

- Examine willingness to participate (WTP) in HIV cure-related research using the HIV Cure Pessimism Scale in conjunction with other validated instruments measuring **psychosocial correlates, barriers** and **facilitators** to research participation (e.g., Barriers to Research Participation Questionnaire, Kibler & Brisco, 2006).
- Ensure that ongoing research examines both HIV cure pessimism and WTP among populations that are often underrepresented in HIV cure-related research (e.g., women; racial/ethnic minorities; sexual & gender minorities; younger populations; older adults; long-term HIV survivors (all ages); persons with education level of high school diploma or less; persons living in rural areas, the Southern and Midwest United States; and international populations).
- Through quantitative and qualitative methods, assess attitudes toward analytical treatment interruption (ATI), including as they relate to WTP in HIV cure-related research.
- Future research, recruitment, and retention strategies may benefit from knowledge and best practices in the HIV prevention and HIV vaccine clinical trial arenas.

The defeatHIV Community Advisory Board

OUR MISSION

To serve as a communication link and mobilize HIV cure researchers, their institutions and our communities to work together to cure HIV



Social Justice – inclusion, access, equity



Messaging -- Being intentional and attentive to language impact regarding cure research

OUR PRIORITIES



Aligning researchers and community members to achieve research success



Building trusting relationships with communities



Developing science/research literacy, development of skills and personal growth among CAB members



Creating a **diverse CAB** that ensures that input from people living with HIV is accounted for in all CAB decisions



Engaging Community

Host community forums with HIV cure research experts



Provide opportunities for community members to meet **Timothy Ray Brown**, the only person to be considered cured of HIV



Outreach at events such as gay pride, AIDS fundraising events, health fairs, etc.



Outreach to targeted community groups we go to them



Webinars highlighting gene therapy and stem cell transplantation research



Extensive use of **social media** for advertising and posting event recordings



Open door invitation for community members to come to CAB meetings



Bringing Community to Cure

Laurie Sylla¹, Erick Seelbach¹, Arjun Jay Kumar¹, Thomas Andrus² and Michael Louella^{1,2}

¹defeatHIV Community Advisory Board ²defeatHIV, Fred Hutchinson Cancer Research Center, Seattle, WA

Influencing Research



Are integrated members of collaborative **executive** and **scientific core** committees



Provide feedback to researchers on study protocols, consents, recruitment and compensation policies



Engage in **advocacy** on timely issues: materials transfer agreement (to obtain medications for animal studies); need for nonhuman primate research; appropriate funding for cure research; community involvement as required structural component of cure research collaborations in new federal funding cycle

OUR MEMBERS



Engage in **CAB self-education** – attend scientific meetings; bring speakers to CAB meetings to assure we are **informed advocates**



Obtain corporate support for community members to attend scientific meetings



Nurture and maintain a **valued partnership** between researchers and community

Acknowledgments

We would like to thank the members of the defeatHIV CAB, both past and present, who have taught us that nobody can do everything, but everyone can do something: Arjun Jay Kumar; Abe Gaston III; Bill Hall; Brandon Aguirre-Rendon; Erick Seelbach; Gavin Green; John Sigala; J.T. Munny; J. Wong; Kellan Dapary; Kim Ryan; Ryan Sawyer; Larry Pyle; Laurie Sylla; Lindsay Saenz; Manuel Venegas; Michael Barnes; Michael Louella; Mitch Arnone; Paris Mullen; Robert Reinhard; Stephanie Dayo; Tranisha Arzoh.

Results

Reached thousands of community members with accurate and responsible cure information

FROM JULY 1, 2014 TO JUNE 30, 2015

56,597*

ENGAGEMENTS WITH HIV CURE RESEARCH

*ESTIMATED BY ATTENDING, FOLLOWERS, SUBSCRIBERS & AD PLACEMENTS

DUPLICATIONS ACROSS MEDIA FROM UNCURE INDIVIDUALS NOT ACCOUNTED FOR IN THIS TOTAL



IN THEIR WORDS....

I must admit I dream of a cure too, so I'll always be here for my little girl. Who is 6 now, and I am 30 and terrified. I am sorry to speak like this, but I never talked to anyone that had the science and hope behind it.... You don't know me but I'm forever grateful for this day and your knowledge. Thanks again. - Melissa M., community member

Due to its commitment to welcoming as members local stakeholders as well as any person drawn by news about cure research happening in Seattle, the defeatHIV CAB proves time and again invaluable to our team, our institution and to their own communities, thereby helping everyone navigate new, unfamiliar territory to avoid misunderstandings, communicate effectively and, most importantly, to listen to each other.

- Keith R. Jerome, MD, PhD and Hans-Peter Klem, MD, co-Principal Investigators, defeatHIV



CUREiculum

community engagement

WE'RE SCARED.... AND BRAVE: Potential Trial Participant Expectations of HIV Cure Researchers

Sylla L,¹ Evans D,² Taylor J,³ Palm D,³ Gilbertson A,⁴ Dubé K.⁴

¹ defeatHIV Community Advisory Board; ² Delaney AIDS Research Enterprise (DARE) CAB; ³ Collaboratory of AIDS Researchers for Eradication (CARE) CAB; ⁴ UNC Chapel Hill

Abstract

Background: Clinical studies exploring methodologies leading to a functional or an eradicating cure are a new field in HIV research, with unique physiological and psychological risks and potential benefits to participants. This study endeavored to learn about potential participants' motivations to participate in these studies, barriers to participation, perceptions of what an HIV cure would mean, and expectations related to participating in HIV cure research.

Methods: A cross-sectional survey of 400 HIV+ adults was conducted, followed up by nine focus groups in California, North Carolina and Seattle, Washington. Focus group discussions included questions specific to what individuals expected of HIV cure researchers and what they wanted researchers to know.

Results: These results are from a subset of questions from the four Seattle focus groups that included 33 participants. Participants wanted research teams to understand the psychological trauma experienced by many people living with HIV, particularly past and ongoing stigma, to be respectful of them as whole human beings, to "get them," to be honest and transparent about all study risks and procedures, to compensate them fairly, and to have study team members and visits available to them after hours. Participants also endorsed having someone with a mental health background as part of the study team. Non-white participants expressed desire for study teams to include members who were reflective of participants. Participants expressed significant concerns about risk to their health, study procedures, side effects, and lack of durability of a functional cure. Women had specific concerns related to reproductive health and the impact side effects might have on their responsibility to care for others. Some wanted researchers to be mindful that they were as essential to the research as the researchers.

Conclusions: Honest, respectful relationships between participants and researchers, with transparency, appropriate compensation, and safety planning will be necessary for recruiting and retaining cure trial participants. Taking participant concerns and expectations into account will contribute to the success of HIV cure research.

SEATTLE FOCUS GROUP DEMOGRAPHICS

Age	Gender	Race	Sexual Orientation	Time in Seattle	Time in US
18-24	1	Black/African American	1	1	1
25-34	1	Black/African American	1	1	1
35-44	1	Black/African American	1	1	1
45-54	1	Black/African American	1	1	1
55-64	1	Black/African American	1	1	1
65+	1	Black/African American	1	1	1
Total	5	5	5	5	5

As part of a larger study, four focus groups of people living with HIV were conducted in Seattle, WA, with a total of 33 participants. Separate groups were conducted for: women, long-term survivors (20+ years), Latino gay men, and young adults (<50 years old). Stigma interfered with recruitment for an intended transgender women's group. The long-term survivor group was largest, resulting in half of our participants being over 50, and more than 2/3 diagnosed pre-HAART. Group focus impacted participant demographics, which are not a representative sample. IDU prevalence in Seattle/King County is <5%.

WHAT PARTICIPANTS SAID THEY EXPECT/WANT FROM HIV CURE RESEARCHERS

EXPERTISE/PROFESSIONALISM EXPECTATIONS

- Professional
- Scientifically competent
- Culturally aware/competent/reflective
- Trauma-Informed Care competence
- Researcher/Institution reputation
- Knowledgeable
- Researcher stability
- Knowledgeable about hormones and their interplay

INFORMATIONAL EXPECTATIONS

- Ask thorough questions
 - Pre-study visit, benefits
 - What you do and don't know about potential risks
- Update participants on research progress
- How will you compensate me for study time? If something bad happens to me?
- Transparency regarding researchers who can speak in Spanish - not translated

RELATIONAL/INTERACTIONAL EXPECTATIONS

- Treated with RESPECT
 - Respect means able to make participants feel comfortable
 - Able to establish trust
 - Reduce the fear/embarrassment
 - Culturally sensitive
 - Respect my time
 - Take time with me
 - Be patient - especially if I don't understand questions or treatments
- Be sensitive to impact of stigma
 - Education
 - I'd want someone who could help me, comfort me if I'm crying, that's important
 - Someone should be available 24/7 - a hot person
 - They should talk to me in terms I can understand
 - They should be open and honest - no hidden agenda

EXPECTATIONS RE: RESEARCHERS' VIEWS OF PARTICIPANTS

- See participants as unique, whole individuals
- Researchers should not be objectifying
- They should be thankful you're there
- They should understand what the community needs. They need to "get the community."

"They need to remember that they need us at least as much as we need them."

"WE'RE SCARED... AND BRAVE...."

It takes courage to participate in cure research. Participants want empathy. They want to feel seen, understood and respected. They want to be seen as partners in research.

"HOW MANY OF THEM HAVE BEEN RESEARCHED? NOT JUST DOING IT FOR OTHERS, BUT HOW MANY OF THEM HAVE BEEN DOING IT, HAVE BEEN IN RESEARCH?"

Discussion

Participants are making themselves vulnerable to researchers- physically and emotionally. They are inconveniencing themselves and taking time out of their lives. They are trusting the study team and want to feel personally connected to them. They want to be treated with the dignity, respect, and support they deserve for putting themselves on the line.

BE AWARE OF MENTAL HEALTH CONCERNS

- Researcher awareness for mental health and possibly assessing the change health is the important up to date health
- What is potential impact of researchers on participants' mental health?
- Will mental health history be addressed/asked about?
- Individual treatment changes are ok
- Be aware changes in depression, anxiety, etc., could be an indication of stress
- Don't expect us to be happy
- Understand impact of stigma on participants. Be aware of stigmatizing language

SOME OPERATIONAL SUGGESTIONS

- After hours availability of study staff
- Dedicated support group for study participants
- Have resources available for mental health, substance abuse, HIV stigma
- Mental health specialists available to consult to researchers
- Social workers/counselors available
- Provide incentives to keep people engaged. Use a chance to win free groceries
- FREE PARKING would make a difference

AND FURTHERMORE....

- Want to be culturally and linguistically understood by researchers
- Don't want the cure to be worse than what we have now (side effect concerns)
- 2% already tested, concerned about being excluded
- The cure should be worth a quality of life
- We appreciate what they are doing
- Keep up the good work

Significance



Studies that recognize community member concerns and meet their needs and that are carried out with respect and empathy will be more likely to be successful with recruitment and retention of all people living with HIV, and thus more likely to bring us closer to a cure more quickly.

Acknowledgements: defeatHIV CAB members: Bill Hall, Manuel Venegas, Tranche Arzak, Host Sites: Madison Clinic, HEYO Life long, AIDS Healthcare Foundation, Brno Hermanos; Most importantly: Focus Group Participants



community engagement

Events




COMMUNITY FORUMS:

CURED/NOT CURED: A TALE OF TWO DIAGNOSES



Click on the underlined text to get other ideas for your events.



- A community forum with Dr. Timothy Henrich and Gary Steinkohl to discuss the research around Boston Patients and its implications for people living with HIV
- Hosted by 3 advocate representing the spectrum of experience of living with HIV who led the conversation
- 89 people attended

COMMUNITY FORUMS:

CURED/NOT CURED: A TALE OF TWO DIAGNOSES


the Stranger THINGS TO READ - THINGS TO DO -

Home / Event Calendar / Readings & Talks / CURED/NOTCURED: A Tale of Two Diagnoses

CURED/NOTCURED: A Tale of Two Diagnoses

★ Recommended, Don't Miss

TALK Fred Hutchinson Cancer Research Center (map) South Lake Union
Wed Aug 3, 7–9 pm



FREE

In 2007, Gary Steinkohl received a bone marrow transplant that doctors hoped would cure him of HIV—and for a few months, they thought it had. But shortly after lead researcher Dr. Timothy Henrich gave an optimistic conference talk about the procedure, the virus reappeared, dashing hopes of having found a cure. As patient and scientist, Steinkohl and Henrich are now reflecting on the experience in a free community Q&A. They'll cover the science behind the procedure, the emotional impact of having found what they thought was a cure, and what researchers and patients today can learn from their experience. MATT BAUME

EVENT PLANNING TIP: Create a press release for your event and send it to your local media, including newspapers, radio and TV news.

- KING 5 TV NEWS segment
- KOMO Radio interviews with Dr. Henrich and Mr. Steinkohl
- Entry into The Stranger Suggests calendar (a popular Seattle publication)
- Recorded by the Seattle Channel and posted to the defeatHIV YouTube channel